CorMedix Posts Strong 2025 Results, Eyes Key Clinical Milestones
Event summary
- CorMedix reported Q4 2025 net revenue of $128.6M, up from $31.2M in Q4 2024, driven by DefenCath sales and Melinta portfolio integration.
- Full-year 2025 pro forma revenue reached $401.3M, with net income of $163M compared to a $17.9M loss in 2024.
- Company launched $75M share repurchase program in February 2026.
- Phase 3 ReSPECT study results for REZZAYO expected in Q2 2026.
- Cash and short-term investments stood at $148.5M as of December 31, 2025.
The big picture
CorMedix's strong 2025 performance reflects successful integration of the Melinta acquisition and robust demand for DefenCath. The company is positioning itself for further growth through key clinical milestones and shareholder returns. The biopharmaceutical sector's focus on anti-infective solutions and the competitive landscape will shape CorMedix's strategic trajectory in the coming years.
What we're watching
- Clinical Milestones
- The timing and results of the Phase 3 ReSPECT study for REZZAYO will be critical for CorMedix's growth prospects in 2026.
- Integration Challenges
- The company's ability to sustain the operational and financial benefits from the Melinta acquisition will be key to meeting 2026 guidance.
- Capital Allocation
- The pace and execution of the $75M share repurchase program will signal management's confidence in the company's valuation and future cash flows.
Related topics